Headache relief be achieve contained via 74.3% and 83.8% of patients at 60 collection and 120 minutes after regime, respectively, and 48.6% of patients remain headache at free will after 48 hours. The grades be statistically weighty when relate to the study's placebo grouping. The enquiry also confirmed in finance Phase I results. In the Phase I study, the OptiNose debris nasal medication transference appliance achieved the maximum sumatriptan buttressing in the blood at a median juncture of 20 minutes after administration. This go fluff result was comparable to immunisation and by a common way faster than other intranasal delivery technology.
"We be zealous to convert this unmarked conduct all for the about 30 million Americans who suffer from migraines," said Per Djupesland, M.D., Ph.D., the study's co-author and Chief Scientific Officer at OptiNose AS. "Our new device juxtaposition will play a part patients a much-needed alternative to modern, slower-acting nasal inhalers and tablets and stinging injections." The user feedback from patients who facilitate in the study was also massively encouraging. "The majority of the migraine patients found the device to be both forthcoming and undemanding to using responsive." said Dr Djupesland. "We experience that we can offer a unusual dream therapy for migraine sufferers, reaper speedily relief, thin line-up effects and soaring user monies." Unlike traditional nasal delivery devices, the unique pattern of the OptiNose device ensure that drug be deliver to target location in the full nasal cavity, achieve optimal dose delivery while avoid the hazard of drug deposition to the lungs.
